Florida CBD Market Insights under Farm Bill

Mar.04.2023
Florida CBD Market Insights under Farm Bill
Florida's CBD market grows after the "Farm Bill" passed in 2018, but regulations remain a challenge for industry insiders like Jordan.

Statement:


This article is solely focused on conducting research on related industries and foreign markets. It does not recommend any specific products and does not comment on any domestic policies related to the subject matter.


The legality of the products mentioned in the article only applies to their local overseas markets. Domestic readers are advised to take note and strictly adhere to relevant laws and regulations in China.


This article does not constitute any investment or consumption advice.


This article is not suitable for minors.


On the first day of the Asia Pacific Expo, 2FIRSTS conducted an exclusive interview with Jordan, a representative for CBD dealers in Florida. Jordan provided insights into the CBD market in the state of Florida.


The "Farm Bill" promotes the development of the marijuana market.


In 2014, the state of Florida passed the "Compassionate Medical Cannabis Act," which allowed some patients to use medical marijuana and low-THC cannabis.


What has truly fueled the booming CBD market in Florida is the Farm Bill introduced by the United States in 2018.


According to Jordan, this bill essentially opens the door for certain requirements to be met by marijuana products, with the most noteworthy aspect being the release of cannabinoids, including non-psychoactive cannabidiol (CBD), from federal regulation.


Jordan emphasized a key point to 2FIRSTS, stating that as long as the Delta-9 THC content is below 0.3%, it is classified as hemp rather than marijuana.


After the enactment of this law, products can be legally manufactured, sold, and transported as long as they comply with the federal regulations on ingredients limits and labeling requirements.


However, the implementation of regulations in different states may vary. For example, Florida has stricter regulations regarding marijuana. "First, one must have a lab that has a QR code to test all substances in the sample, including the levels of THC and CBD in marijuana, as well as testing for mold, heavy metals, and pesticides," said Jordan.


You never know when new regulations may be implemented.


Although there are existing regulations at the macro level, government regulation in response to the development of the CBD market is not set in stone and will be adjusted over time as new issues arise. For distributors like Jordan, it is important to ensure clear and transparent product ingredients and avoid any gray areas or potential bans.


Jordan stated, "Because you never know when there will be new regulations. The regulatory authorities could change the rules as early as tomorrow.


In recent years, the United States has become increasingly tolerant towards recreational marijuana. Jordan himself holds an optimistic view towards the potential future legalization of recreational marijuana in Florida, believing that it's only a matter of time. Data seems to support his optimistic outlook - as of February 2023, 21 states and Washington D.C. have legalized recreational marijuana, a stark contrast to the zero states that had done so prior to November 2011.


How will the market develop in the future?


From the perspective of someone who is focusing on CBD products, the rapid changes in the US consumer market are even difficult for industry insiders to predict. He cited the example of the rise of psychedelic mushrooms in the US market last year. Prior to this, there had never been such a product on the market, and no one could have predicted the emergence of this dark horse.


Jordan stated, "The industry is increasingly turning to psychedelic mushrooms and other alternative smoking products, while consumers are also placing greater attention on health.


According to Jordan, the CBD market in Florida has great potential for growth, especially with the gradual relaxation of marijuana regulations and increased awareness among consumers of health benefits. This may lead to an emergence of more innovative products and demand in the market.


However, for industry professionals, the challenge of operating in a constantly changing regulatory environment remains significant. Regardless of how the market may shift in the future, Jordan states that his focus will always be on providing high-quality CBD products to consumers.


2FIRSTS will continue to cover the APE exhibition and we look forward to bringing you the latest updates and reports.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Mesa Underwriters Specialty Insurance Company has asked a federal court in Washington to declare that it has no duty to defend or indemnify vape distributor i5 Distribution in a product liability case involving an Elf Bar BC5000. The plaintiff alleges that the disposable vape caught fire and exploded in his pocket, causing severe burns and ultimately requiring an above-the-knee amputation of his left leg. MUSIC is relying on a tobacco, nicotine or nicotine replacement products exclusion and a premises limitation endorsement. The court has not ruled on the coverage dispute.
News
Sep.10
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04